ADMA Biologics
ADMA
56 hedge funds and large institutions have $84.5M invested in ADMA Biologics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
46% more capital invested
Capital invested by funds: $58M → $84.5M (+$26.5M)
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.18% less ownership
Funds ownership: 53.28% → 48.1% (-5.2%)
84% less call options, than puts
Call options by funds: $297K | Put options by funds: $1.81M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$795K |
| 3 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
+$619K |
| 4 |
Barclays
London,
United Kingdom
|
+$195K |
| 5 |
Jane Street
New York
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$9.71M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.23M |
| 3 |
DG
Delek Group
Herzliya,
Israel
|
-$193K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$131K |
| 5 |
Morgan Stanley
New York
|
-$90.3K |
ADMA Hedge Fund Activity: Q1 2019 in Review
56 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2019, worth a combined $84.5M — up 46% from $58M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADMA positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.19M. The largest seller was Broadfin Capital, cutting an estimated $9.71M.
- 56 institutional investors held ADMA Biologics (ADMA) as of Q1 2019, up from 52 in Q4 2018.
- Funds reported $84.5M of ADMA Biologics stock for Q1 2019, up 46% quarter-over-quarter.
- 10 funds opened new ADMA Biologics positions in Q1 2019 and 5 closed out, a net change of +5 holders.
- The largest ADMA Biologics buyer in Q1 2019 was Vanguard Group, an estimated $1.19M added.
- The largest ADMA Biologics seller in Q1 2019 was Broadfin Capital, an estimated $9.71M sold.
Based on aggregated 13F filings for Q1 2019.